NeOnc CEO Buys More Shares Below $5 as NTHI Secures FDA Meeting to Discuss Phase 3 Trial
Globe Newswire•12/11/2026•10:13 ET
0
Key Highlights
- ➤CEO Amir Heshmatpour bought 70,000 shares, lifting November purchases to 150,000
- ➤NeOnc scheduled FDA Type B meeting for early January 2027
- ➤FDA meeting will discuss accelerated approval for intranasal NEO100
- ➤Proposed NEO100-012 Phase 3 trial would use overall survival as primary endpoint
- ➤NTHI short interest rose to approximately 921,000 shares by October 30
DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones.
The latest transactions represent approximately $294,500, with purchases reaching $4.49 per share. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately $563,582 across November 5–11.
Get started
Create a free account to read the full story.